Donners MM et al. |
Low-dose FK506 blocks collar-induced atherosclerotic plaque development and stabilizes plaques in ApoE-/- mice. |
2005 |
Am. J. Transplant. |
pmid:15888024
|
Lemahieu W et al. |
Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea. |
2005 |
Am. J. Transplant. |
pmid:15888045
|
Campbell PM et al. |
Pretransplant HLA antibodies are associated with reduced graft survival after clinical islet transplantation. |
2007 |
Am. J. Transplant. |
pmid:17456201
|
Singh K et al. |
Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. |
2014 |
Am. J. Transplant. |
pmid:25359003
|
Dugast E et al. |
Failure of Calcineurin Inhibitor (Tacrolimus) Weaning Randomized Trial in Long-Term Stable Kidney Transplant Recipients. |
2016 |
Am. J. Transplant. |
pmid:27367750
|
Tang Q |
Pharmacokinetics of therapeutic Tregs. |
2014 |
Am. J. Transplant. |
pmid:25358900
|
Wen X et al. |
Comparison of Utilization and Clinical Outcomes for Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients. |
2016 |
Am. J. Transplant. |
pmid:27137884
|
Sikma MA et al. |
Pharmacokinetics and Toxicity of Tacrolimus Early After Heart and Lung Transplantation. |
2015 |
Am. J. Transplant. |
pmid:26053114
|
Ellis CL and Racusen LC |
Mild rise in creatinine six months post kidney transplant. |
2012 |
Am. J. Transplant. |
pmid:22845913
|
English RF et al. |
Long-term comparison of tacrolimus- and cyclosporine-induced nephrotoxicity in pediatric heart-transplant recipients. |
2002 |
Am. J. Transplant. |
pmid:12243498
|
de Fontbrune FS et al. |
Veno-occlusive disease of the liver after lung transplantation. |
2007 |
Am. J. Transplant. |
pmid:17697264
|
Abdelmalek MF et al. |
Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. |
2012 |
Am. J. Transplant. |
pmid:22233522
|
Boudjema K et al. |
Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. |
2011 |
Am. J. Transplant. |
pmid:21466650
|
Knechtle SJ |
Guidance for liver transplant immunosuppression. |
2011 |
Am. J. Transplant. |
pmid:21466652
|
Gupta G et al. |
Safe Conversion From Tacrolimus to Belatacept in High Immunologic Risk Kidney Transplant Recipients With Allograft Dysfunction. |
2015 |
Am. J. Transplant. |
pmid:25988397
|
Wang Q et al. |
Biodegradable microsphere-loaded tacrolimus enhanced the effect on mice islet allograft and reduced the adverse effect on insulin secretion. |
2004 |
Am. J. Transplant. |
pmid:15084166
|
Schubert M et al. |
Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. |
2004 |
Am. J. Transplant. |
pmid:15084173
|
ter Meulen CG et al. |
Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: a prospective, randomized, multicenter study. |
2004 |
Am. J. Transplant. |
pmid:15084178
|
Silva HT et al. |
Planned randomized conversion from tacrolimus to sirolimus-based immunosuppressive regimen in de novo kidney transplant recipients. |
2013 |
Am. J. Transplant. |
pmid:24266969
|
Ricciardelli I et al. |
Rapid generation of EBV-specific cytotoxic T lymphocytes resistant to calcineurin inhibitors for adoptive immunotherapy. |
2013 |
Am. J. Transplant. |
pmid:24266973
|
Hernández-Fisac I et al. |
Tacrolimus-induced diabetes in rats courses with suppressed insulin gene expression in pancreatic islets. |
2007 |
Am. J. Transplant. |
pmid:17725683
|
Suszynski TM et al. |
Prospective randomized trial of maintenance immunosuppression with rapid discontinuation of prednisone in adult kidney transplantation. |
2013 |
Am. J. Transplant. |
pmid:23432755
|
Damon C et al. |
Predictive Modeling of Tacrolimus Dose Requirement Based on High-Throughput Genetic Screening. |
2017 |
Am. J. Transplant. |
pmid:27597269
|
Ferguson R et al. |
Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. |
2011 |
Am. J. Transplant. |
pmid:21114656
|
McKenna G and Trotter JF |
Does early (CNI) conversion lead to eternal (renal) salvation? |
2010 |
Am. J. Transplant. |
pmid:20928938
|
Shuker N et al. |
A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype-Based With Body-Weight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation. |
2016 |
Am. J. Transplant. |
pmid:26714287
|
MacPhee IA et al. |
The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. |
2004 |
Am. J. Transplant. |
pmid:15147425
|
Artz MA et al. |
Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. |
2004 |
Am. J. Transplant. |
pmid:15147428
|
Klintmalm GB |
Immunosuppression, generic drugs and the FDA. |
2011 |
Am. J. Transplant. |
pmid:21794082
|
Böger CA et al. |
Reverse diastolic intrarenal flow due to calcineurin inhibitor (CNI) toxicity. |
2006 |
Am. J. Transplant. |
pmid:16889550
|
Forns X and Navasa M |
Cyclosporine A or tacrolimus for hepatitis C recurrence? An old debate. |
2011 |
Am. J. Transplant. |
pmid:21797970
|
Tan HP et al. |
Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. |
2006 |
Am. J. Transplant. |
pmid:16889606
|
Wlodarczyk Z et al. |
Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. |
2009 |
Am. J. Transplant. |
pmid:19681813
|
Chisholm-Burns MA et al. |
Immunosuppressant therapy adherence and graft failure among pediatric renal transplant recipients. |
2009 |
Am. J. Transplant. |
pmid:19681814
|
Schold JD and Kaplan B |
AZA/tacrolimus is associated with similar outcomes as MMF/tacrolimus among renal transplant recipients. |
2009 |
Am. J. Transplant. |
pmid:19681827
|
Arnold R et al. |
Association between calcineurin inhibitor treatment and peripheral nerve dysfunction in renal transplant recipients. |
2013 |
Am. J. Transplant. |
pmid:23841745
|
Hirsch HH et al. |
BK Polyomavirus Replication in Renal Tubular Epithelial Cells Is Inhibited by Sirolimus, but Activated by Tacrolimus Through a Pathway Involving FKBP-12. |
2016 |
Am. J. Transplant. |
pmid:26639422
|
Gregoor PS and Weimar W |
Tacrolimus and pure red-cell aplasia. |
2005 |
Am. J. Transplant. |
pmid:15636632
|
Busque S et al. |
Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. |
2009 |
Am. J. Transplant. |
pmid:19660021
|
Bohl DL et al. |
Donor origin of BK virus in renal transplantation and role of HLA C7 in susceptibility to sustained BK viremia. |
2005 |
Am. J. Transplant. |
pmid:16095500
|
Kasahara M et al. |
Living-donor liver transplantation for hepatoblastoma. |
2005 |
Am. J. Transplant. |
pmid:16095502
|
Lemahieu WP et al. |
Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. |
2005 |
Am. J. Transplant. |
pmid:16095503
|
Meier-Kriesche HU et al. |
Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. |
2005 |
Am. J. Transplant. |
pmid:16095509
|
RodrÃguez-Perálvarez M et al. |
Tacrolimus exposure after liver transplantation in randomized controlled trials: too much for too long. |
2013 |
Am. J. Transplant. |
pmid:23621166
|
Gao R et al. |
Effects of immunosuppressive drugs on in vitro neogenesis of human islets: mycophenolate mofetil inhibits the proliferation of ductal cells. |
2007 |
Am. J. Transplant. |
pmid:17391142
|
Tremblay S et al. |
A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study. |
2017 |
Am. J. Transplant. |
pmid:27340950
|
Madeleine MM et al. |
HPV-related cancers after solid organ transplantation in the United States. |
2013 |
Am. J. Transplant. |
pmid:24119294
|
Lemahieu WP et al. |
CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus. |
2004 |
Am. J. Transplant. |
pmid:15307840
|
Vongwiwatana A et al. |
Peritubular capillary changes and C4d deposits are associated with transplant glomerulopathy but not IgA nephropathy. |
2004 |
Am. J. Transplant. |
pmid:14678043
|
Bressollette-Bodin C et al. |
A prospective longitudinal study of BK virus infection in 104 renal transplant recipients. |
2005 |
Am. J. Transplant. |
pmid:15996241
|
De Simone P et al. |
Everolimus with reduced tacrolimus in liver transplantation. |
2013 |
Am. J. Transplant. |
pmid:23601137
|
Augustine JJ et al. |
Pre-transplant IFN-gamma ELISPOTs are associated with post-transplant renal function in African American renal transplant recipients. |
2005 |
Am. J. Transplant. |
pmid:15996247
|
Filler G et al. |
Adding sirolimus to tacrolimus-based immunosuppression in pediatric renal transplant recipients reduces tacrolimus exposure. |
2005 |
Am. J. Transplant. |
pmid:15996252
|
Froud T et al. |
Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience. |
2005 |
Am. J. Transplant. |
pmid:15996257
|
Shihab F et al. |
Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus. |
2017 |
Am. J. Transplant. |
pmid:28141897
|
Chodoff L and Hamberg KJ |
Response to 'Different preparations of tacrolimus and medication errors'. |
2009 |
Am. J. Transplant. |
pmid:19392982
|
Luther P and Baldwin D |
Pioglitazone in the management of diabetes mellitus after transplantation. |
2004 |
Am. J. Transplant. |
pmid:15575920
|
Cherukuri A et al. |
An analysis of lymphocyte phenotype after steroid avoidance with either alemtuzumab or basiliximab induction in renal transplantation. |
2012 |
Am. J. Transplant. |
pmid:22390816
|
Dahm F et al. |
Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. |
2004 |
Am. J. Transplant. |
pmid:15575921
|
Pascher A et al. |
Protein kinase C inhibitor sotrastaurin in de novo liver transplant recipients: a randomized phase II trial. |
2015 |
Am. J. Transplant. |
pmid:25677074
|
Barth RN et al. |
Vascularized bone marrow-based immunosuppression inhibits rejection of vascularized composite allografts in nonhuman primates. |
2011 |
Am. J. Transplant. |
pmid:21668624
|
Chen G et al. |
A synergistic effect between PG490-88 and tacrolimus prolongs renal allograft survival in monkeys. |
2006 |
Am. J. Transplant. |
pmid:16539628
|
Guirado L et al. |
Efficacy and safety of conversion from twice-daily to once-daily tacrolimus in a large cohort of stable kidney transplant recipients. |
2011 |
Am. J. Transplant. |
pmid:21668633
|
Flechner SM et al. |
The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. |
2011 |
Am. J. Transplant. |
pmid:21668635
|
Budde K |
How to use mTOR inhibitors? The search goes on. |
2011 |
Am. J. Transplant. |
pmid:21668636
|
Chen G et al. |
Anti-CD45RB monoclonal antibody prolongs renal allograft survival in cynomolgus monkeys. |
2007 |
Am. J. Transplant. |
pmid:17227555
|
Grenda R et al. |
A randomized trial to assess the impact of early steroid withdrawal on growth in pediatric renal transplantation: the TWIST study. |
2010 |
Am. J. Transplant. |
pmid:20420639
|
Mazariegos GV et al. |
Dendritic cell subset ratio in tolerant, weaning and non-tolerant liver recipients is not affected by extent of immunosuppression. |
2005 |
Am. J. Transplant. |
pmid:15643991
|
Knechtle SJ et al. |
Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. |
2009 |
Am. J. Transplant. |
pmid:19344431
|
Bahra M et al. |
MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course. |
2005 |
Am. J. Transplant. |
pmid:15644002
|
Asberg A et al. |
Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients. |
2010 |
Am. J. Transplant. |
pmid:20486914
|
Hautz T et al. |
Molecular markers and targeted therapy of skin rejection in composite tissue allotransplantation. |
2010 |
Am. J. Transplant. |
pmid:20353468
|
Montgomery SP et al. |
Efficacy and toxicity of a protocol using sirolimus, tacrolimus and daclizumab in a nonhuman primate renal allotransplant model. |
2002 |
Am. J. Transplant. |
pmid:12118862
|
Ahsan N et al. |
Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation. |
2002 |
Am. J. Transplant. |
pmid:12118902
|
van Hooff JP et al. |
Glucose metabolic disorder after transplantation. |
2007 |
Am. J. Transplant. |
pmid:17511670
|
Silva HT et al. |
One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. |
2007 |
Am. J. Transplant. |
pmid:17217442
|
Heffron TG et al. |
Once-daily tacrolimus extended-release formulation: 1-year post-conversion in stable pediatric liver transplant recipients. |
2007 |
Am. J. Transplant. |
pmid:17511684
|
Moench C et al. |
Tacrolimus monotherapy without steroids after liver transplantation--a prospective randomized double-blinded placebo-controlled trial. |
2007 |
Am. J. Transplant. |
pmid:17511685
|
Patlolla V et al. |
Efficacy of anti-IL-2 receptor antibodies compared to no induction and to antilymphocyte antibodies in renal transplantation. |
2007 |
Am. J. Transplant. |
pmid:17564638
|
Nijhoff MF et al. |
Glycemic Stability Through Islet-After-Kidney Transplantation Using an Alemtuzumab-Based Induction Regimen and Long-Term Triple-Maintenance Immunosuppression. |
2016 |
Am. J. Transplant. |
pmid:26288226
|
Toso C et al. |
Sequential kidney/islet transplantation: efficacy and safety assessment of a steroid-free immunosuppression protocol. |
2006 |
Am. J. Transplant. |
pmid:16611343
|
Lacaille F et al. |
Severe dysimmune cytopenia in children treated with tacrolimus after organ transplantation. |
2006 |
Am. J. Transplant. |
pmid:16611346
|
Chamie K et al. |
The effect of sirolimus on prostate-specific antigen (PSA) levels in male renal transplant recipients without prostate cancer. |
2008 |
Am. J. Transplant. |
pmid:18853950
|
Lefaucheur C et al. |
Renal histopathological lesions after lung transplantation in patients with cystic fibrosis. |
2008 |
Am. J. Transplant. |
pmid:18671673
|
Tedesco-Silva H et al. |
Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses. |
2015 |
Am. J. Transplant. |
pmid:25988935
|
Pech T et al. |
Intestinal regeneration, residual function and immunological priming following rescue therapy after rat small bowel transplantation. |
2012 |
Am. J. Transplant. |
pmid:22974463
|
Kaplan B and Kirk AD |
Tacrolimus and sirolimus: when bad things happen to good drugs. |
2006 |
Am. J. Transplant. |
pmid:16827845
|
McDonald RA et al. |
Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. |
2008 |
Am. J. Transplant. |
pmid:18416737
|
McAlister VC et al. |
Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. |
2006 |
Am. J. Transplant. |
pmid:16827858
|
Gallon L et al. |
Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs. MMF. |
2006 |
Am. J. Transplant. |
pmid:16827862
|
Grenda R et al. |
A prospective, randomized, multicenter trial of tacrolimus-based therapy with or without basiliximab in pediatric renal transplantation. |
2006 |
Am. J. Transplant. |
pmid:16827869
|
Vanhove T et al. |
High Intrapatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients. |
2016 |
Am. J. Transplant. |
pmid:27013142
|
Barbas AS et al. |
Posterior reversible encephalopathy syndrome independently associated with tacrolimus and sirolimus after multivisceral transplantation. |
2013 |
Am. J. Transplant. |
pmid:23331705
|
Gatault P et al. |
Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study. |
2017 |
Am. J. Transplant. |
pmid:27862923
|
Fujishiro J et al. |
Influence of immunosuppression on alloresponse, inflammation and contractile function of graft after intestinal transplantation. |
2010 |
Am. J. Transplant. |
pmid:20642681
|
Martinez F et al. |
High dose epoetin beta in the first weeks following renal transplantation and delayed graft function: Results of the Neo-PDGF Study. |
2010 |
Am. J. Transplant. |
pmid:20642691
|
Miller LW |
Cardiovascular toxicities of immunosuppressive agents. |
2002 |
Am. J. Transplant. |
pmid:12392286
|
Brennan DC et al. |
Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. |
2005 |
Am. J. Transplant. |
pmid:15707414
|
Rogers J et al. |
Effect of ethnicity on outcome of simultaneous pancreas and kidney transplantation. |
2003 |
Am. J. Transplant. |
pmid:14510702
|
Chhabra D et al. |
Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen. |
2013 |
Am. J. Transplant. |
pmid:24007570
|